Mayflower Financial Advisors LLC Has $2.40 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 24th, 2023

Mayflower Financial Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 1.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 58,824 shares of the biopharmaceutical company’s stock after acquiring an additional 1,023 shares during the period. Mayflower Financial Advisors LLC’s holdings in Pfizer were worth $2,400,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 493,584,761 shares of the biopharmaceutical company’s stock valued at $21,599,270,000 after buying an additional 5,139,634 shares during the period. Moneta Group Investment Advisors LLC grew its holdings in shares of Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the period. Morgan Stanley grew its holdings in shares of Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 4.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 73,340,479 shares of the biopharmaceutical company’s stock valued at $3,741,204,000 after buying an additional 3,216,573 shares during the period. Finally, Norges Bank acquired a new position in shares of Pfizer in the 4th quarter valued at $3,150,472,000. Institutional investors and hedge funds own 67.80% of the company’s stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Friday, May 5th. The shares were acquired at an average price of $38.42 per share, for a total transaction of $38,420.00. Following the purchase, the director now owns 5,000 shares in the company, valued at $192,100. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.05% of the stock is owned by company insiders.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Bank of America decreased their price target on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a report on Friday, April 21st. JPMorgan Chase & Co. set a $45.00 price objective on shares of Pfizer in a research report on Monday, February 27th. Morgan Stanley cut their price objective on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. StockNews.com began coverage on shares of Pfizer in a research report on Thursday, May 18th. They issued a “buy” rating on the stock. Finally, Barclays cut their price objective on shares of Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $47.33.

Pfizer Stock Down 1.1 %

Shares of PFE stock opened at $38.30 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37. The firm’s 50-day moving average is $38.71 and its 200-day moving average is $42.73. The stock has a market cap of $216.22 billion, a price-to-earnings ratio of 7.54, a PEG ratio of 1.33 and a beta of 0.64. Pfizer Inc. has a 52-week low of $36.17 and a 52-week high of $54.93.

Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. The company had revenue of $18.28 billion for the quarter, compared to analysts’ expectations of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. Pfizer’s quarterly revenue was down 28.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.62 EPS. Sell-side analysts predict that Pfizer Inc. will post 3.35 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.28%. Pfizer’s payout ratio is 32.28%.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.